Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial.
Dinneen E, Almeida-Magana R, Al-Hammouri T, Pan S, Leurent B, Haider A, Freeman A, Roberts N, Brew-Graves C, Grierson J, Clow R, Williams N, Aning J, Walton T, Persad R, Oakley N, Ahmad I, Dutto L, Briggs T, Allen C, Tandogdu Z, Adshead J, Oxley J, Kelly J, Shaw G; NeuroSAFE PROOF Investigators.
Dinneen E, et al.
Lancet Oncol. 2025 Apr;26(4):447-458. doi: 10.1016/S1470-2045(25)00091-9. Epub 2025 Mar 24.
Lancet Oncol. 2025.
PMID: 40147459
Free article.
Clinical Trial.